Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 30Ganglioneuroblastoma 7Osteosarcoma 3Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neoplasms 1Neoplasm, Residual 1Medulloblastoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 8Temozolomide 6Topotecan 5Melphalan 5Granulocyte Colony-Stimulating Factor 5X-Rays 4Phantoms, Imaging 4Irinotecan 4palbociclib 3fludarabine 3Vincristine 3Specimen Handling 3Sirolimus 3Magnetic Resonance Spectroscopy 3Busulfan 3Bone Marrow Transplantation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2ivosidenib 2irinotecan sucrosofate 2cabozantinib 2abemaciclib 2Zoledronic Acid 2Vemurafenib 2Nuclear Medicine Department, Hospital 2Nivolumab 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × dinutuximab × CNS × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡